Aesthetics Pipeline

Eluminex’s GMP manufacturing facility dedicated to the production of full-length triple helix recombinant human collagen (Type III and Type I) is located in Suzhou BioBAY and wholly owned and operated by Eluminex.

  • Discovery
  • Preclinical
  • PMA Studies

EB-201:

Full-length triple helix rhCIII 0.3% lidocaine

Approval estimated 2026

EB-202:

Full-length triple helix rhCIII with enhanced cross-linking compared to EB-201 and 0.3% lidocaine

EB-203:

Full-length triple helix rhCI & rhCIII with 0.3% lidocaine

EB-204:

Full-length triple helix rhCIII and hyaluronic acid with 0.3% lidocaine

EB-201

EB-201 is the world’s first full-length triple helix recombinant human type III collagen (rhCIII) under development as a premium non-immunogenic injectable aesthetic dermal filler to improve skin quality.  EB-201 is designed to replace type III collagen that is naturally lost due to aging and sun exposure that leads to fine lines, wrinkles, and loss of dermal elasticity. EB-201 completed preclinical studies and is currently under PMA-enabling development with first market entry anticipated for China.

EB-202

EB-202 is the world’s first full-length, triple helix rhCIII with enhanced cross-linking to extend aesthetic rejuvenation durability. EB-202 early research and development work has been completed.

EB-203

EB-203 is under development as the world’s first blend of full-length, triple helix recombinant human type I (rhCI) and type III collagen (rhCIII) under development as a premium non-immunogenic injectable aesthetic dermal filler to improve skin quality.  EB-203 is designed to replace type I and type III collagen that is naturally lost due to aging leading to decreased skin quality.

EB-204

EB-204 is under development as the world’s first blend of full-length triple helix rhCIII and hyaluronic acid (HA) as a premium, next-generation dermal filler that provides the best of both collagen replacement and HA performance.